Patents by Inventor John J. Baldwin

John J. Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4968713
    Abstract: A method for inhibiting transglutaminase activity, especially Factor XIIIa activity with certain imidazole compounds is described. The imidazole compounds are those selected from(A) a imidazole having the formula ##STR1## or its acid addition salt, and ##STR2## wherein: R is hydrogen or lower alkyl;R.sup.1 is lower alkyl;R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl;R.sup.4 is lower alkyl; andX is the negative radical of a pharmaceutically acceptable salt.Also described are compositions suitable for use in inhibiting transglutaminase activity.
    Type: Grant
    Filed: July 31, 1989
    Date of Patent: November 6, 1990
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon
  • Patent number: 4945182
    Abstract: Hydroxyalkyl-phenoxy-propan-2-ol-3-amines are oculoselective .beta.-blockers useful in the treatment of elevated intraocular pressure with little or no effect on the pulmonary or cardiovascular system.
    Type: Grant
    Filed: September 29, 1986
    Date of Patent: July 31, 1990
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, David C. Remy, David A. Claremon
  • Patent number: 4929637
    Abstract: Thiophene-2-sulfonamides with an alkyl or substituted-alkyl and an alkyl-S(O).sub.n -substituent are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.
    Type: Grant
    Filed: December 14, 1988
    Date of Patent: May 29, 1990
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Charles N. Habecker
  • Patent number: 4916223
    Abstract: Certain substituted hexahydroarylquinolizines and pharmaceutically acceptable salts thereof are peripherally selective .alpha..sub.2 -adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.
    Type: Grant
    Filed: February 6, 1989
    Date of Patent: April 10, 1990
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Joel R. Huff, Susan J. DeSolms, Joseph P. Vacca, Jonathan M. Wiggins, Steven D. Young
  • Patent number: 4889856
    Abstract: 7,8-Dihydro-4-(1-piperazinyl)-6H-thiopyranopyrimidines have .beta.-adrenergic blocking properties and are thus useful in the treatment of cardiovascular ailments known to be amenable to .beta.-blocker therapy. Certain of the compounds are useful in the treatment of elevated intraocular pressure by topical ocular administration.
    Type: Grant
    Filed: August 31, 1987
    Date of Patent: December 26, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Tolman, Arthur F. Wagner, John J. Baldwin, Adolph Pietruszkiewicz
  • Patent number: 4883814
    Abstract: 1-Aryloxy-3-(substituted alkylamino)-2-propanols having the general information: ##STR1## and their pharmaceutically acceptable salts exhibit cardioselective .beta.-adrenergic blocking activity, and are useful as antihypertensive, cardioprotective, antiarrhythmic and, antianginal agents.
    Type: Grant
    Filed: July 7, 1988
    Date of Patent: November 28, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Patent number: 4871739
    Abstract: There are disclosed certain 2-substituted-4-substituted 6H-7,8-dihydrothiapyrano[3,2-d]pyrimidines which have oral hypoglycemic activity and with such ability to lower blood sugar are useful in the treatment of type II diabetes and/or obesity with associated insulin resistance. Processes for the preparation of such compounds and compositions containing such compounds as the active ingredient thereof are also disclosed. The compounds are also .beta.-adrenergic blocking agonists or .alpha.-adrenergic blocking agents and act as ocular antihypertensives and are useful for the treatment of glaucoma and other eye disorders.
    Type: Grant
    Filed: January 21, 1987
    Date of Patent: October 3, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Richard L. Tolman, Mu T. Wu
  • Patent number: 4863922
    Abstract: Aromatic sulfonamides with a saturated heterocycle fused thereto are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.
    Type: Grant
    Filed: June 15, 1988
    Date of Patent: September 5, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Marcia E. Christy
  • Patent number: 4853383
    Abstract: Novel substituted imidazoles and methods for their preparation are disclosed. These imidazoles, and their salts, exhibit pharmacological activity which includes antihypertensive activity and .beta.-adrenergic blocking activity.
    Type: Grant
    Filed: September 8, 1986
    Date of Patent: August 1, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Patent number: 4847289
    Abstract: Aryl (or aralkyl)-sulfonylthiophene-2-sulfonamides containing a basic functional group as a substituent are efficacious in the treatment of elevated intraocular pressure and glaucoma following topical ocular administration.
    Type: Grant
    Filed: June 8, 1987
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Charles M. Habecker, Samuel L. Graham, Wasyl Halczenko, George D. Hartman, Harvey Schwam, Gerald S. Ponticello, Kenneth L. Shepard
  • Patent number: 4831035
    Abstract: Certain substituted hexahydroarylquinolizines and pharmaceutically acceptable salts thereof are peripherally selective .alpha..sub.2 -adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.
    Type: Grant
    Filed: July 27, 1987
    Date of Patent: May 16, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Joel R. Huff, Susan J. deSolms, Joseph P. Vacca, Jonathan M. Wiggins, Steven D. Young
  • Patent number: 4824849
    Abstract: Substituted hexahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective .alpha..sub.2 -adrenergic receptor antagonists and thereby useful as antidepressants, antihypertensives, ocular antihypertensives, antidiabetics, platelet aggregation inhibitors, antiobesity agents, and modifiers of gastrointestinal motility.
    Type: Grant
    Filed: August 28, 1987
    Date of Patent: April 25, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Joel R. Huff, Joseph P. Vacca, Steven D. Young, Jane deSolms, James P. Guare, Jr.
  • Patent number: 4816457
    Abstract: Heterocyclic aminoethanols of the formula:Het--CHOH--CH.sub.2 --NH-aralkylwhere Het is a 6-10 membered N-heterocycle are disclosed. The compounds are useful as pharmaceuticals.
    Type: Grant
    Filed: June 30, 1987
    Date of Patent: March 28, 1989
    Inventors: John J. Baldwin, Joseph Atkinson, David E. McClure
  • Patent number: 4810725
    Abstract: 1-Aryloxy-3-(substituted aminoalkylamino)-2-propanols and pharmaceutically acceptable salts thereof have .beta.-adrenergic blocking activity with some cardioselectivity and hence are useful as anti-hypertensive, antianginal, antiarrhythmic and cardioprotective agents and in the treatment of elevated intraocular pressure such as glaucoma.
    Type: Grant
    Filed: October 14, 1986
    Date of Patent: March 7, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Sandor L. Varga
  • Patent number: 4803286
    Abstract: Certain amino-2-hydroxypropyloximinoheterocycles are .beta.-adrenoceptor antagonists useful in the treatment of elevated intraocular pressure, hypertension, angina and arrhythmia.
    Type: Grant
    Filed: August 19, 1987
    Date of Patent: February 7, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, David C. Remy, David A. Claremon, Stella W. King
  • Patent number: 4797413
    Abstract: Aromatic sulfonamides with a saturated heterocycle fused thereto are carbonic anhydrase inhibitors useful in the treatment of elevated intraocular pressure.
    Type: Grant
    Filed: June 26, 1987
    Date of Patent: January 10, 1989
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello, Marcia E. Christy
  • Patent number: 4788193
    Abstract: The 1-aryloxy-3-(substituted alkylamino)-2-propanols of this invention and their pharmaceutically acceptable salts exhibit cardioselective .beta.-adrenergic blocking activity, and are useful as antihypertensive, cardioprotective, antiarrhythmic and, antianginal agents.
    Type: Grant
    Filed: May 18, 1987
    Date of Patent: November 29, 1988
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello
  • Patent number: 4774243
    Abstract: Topical ocular administration of a dopamine agonist is effective in lowering abnormally elevated intraocular pressure and is useful in the prevention and treatment of glaucoma and related ocular diseases.
    Type: Grant
    Filed: December 24, 1985
    Date of Patent: September 27, 1988
    Assignee: Merck & Co., Inc.
    Inventor: John J. Baldwin
  • Patent number: 4735956
    Abstract: Novel substituted 4-heteroaryl-1,4-dihydropyridine compounds useful as calcium channel blockers, pharmaceutical compositions therof, and methods of treatment are disclosed.
    Type: Grant
    Filed: September 13, 1985
    Date of Patent: April 5, 1988
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Wasyl Halczenko, George D. Hartman, Brian T. Phillips
  • Patent number: 4735961
    Abstract: Novel substituted aminohydroxypropoxyphenyl oxazole and thiazole compounds and methods for their preparation are disclosed. These compounds, and their salts exhibit cardioselective .beta.-adrenergic blocking activity, and are useful as antihypertensive, cardioprotective, antiarrhythmic and antianginal agents.
    Type: Grant
    Filed: November 5, 1985
    Date of Patent: April 5, 1988
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Gerald S. Ponticello